SCHEMBL8589404

SCHEMBL8589404

O=C(CCl)Nc1ccc(-c2ccncc2)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 5/20 0.50
LMNA P02545 4/20 0.48
POLB P06746 2/20 0.48
MAPK1 P28482 1/20 0.48
CASP3 P42574 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
NPC1 O15118 2/20 0.46
MITF O75030 2/20 0.46
RAB9A P51151 2/20 0.46
XBP1 P17861 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NOD2 Q9HC29 1/20 0.46
MAPT P10636 2/20 0.46
TP53 P04637 1/20 0.46
THRB P10828 1/20 0.46
RORC P51449 1/20 0.46
ALDH1A1 P00352 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8115604 0.82 ALDH1A1 (0.51) LMNAPOLBMAPK1MEN1KMT2A
SCHEMBL8616595 0.81 LMNA (0.46) GSTO1LMNAPOLBMAPK1CASP3
SCHEMBL8118567 0.80 MEN1 (0.50) LMNAPOLBMAPK1MEN1KMT2A
SCHEMBL30833308 0.76 CYP3A4 (0.71) GSTO1LMNAMEN1KMT2ANPC1
SCHEMBL4003878 0.76 CYP3A4 (0.71) GSTO1LMNAMEN1KMT2ANPC1
SCHEMBL2133754 0.76 BCHE (0.61) LMNAMAPK1CASP3MEN1KMT2A
SCHEMBL10375232 0.75 ALDH1A1 (0.47) MAPK1MEN1KMT2AALDH1A1KDM4E
Hydrochloric Acid SCHEMBL21296615 0.74 BCHE (0.59) LMNAMAPK1CASP3MEN1KMT2A
SCHEMBL7751082 0.73 GSTO1 (0.56) GSTO1LMNACASP3NPC1MITF
SCHEMBL4002460 0.72 TSHR (0.73) LMNAMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1998050346-A2 ACETAMIDE AND UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CNS DISORDERS SMITHKLINE BEECHAM PLC (GB) 1998-11-12 WO disclosed